CosmosID and Zymo Research partner up on microbiome analysis

Zymo Research and CosmosID to deliver integrated solution for accurate microbiome analysis; companies present research at ASM Microbe conference in Atlanta

| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Rockville, Md. and Irving, Calif.—Zymo Research and CosmosID announced today their partnership to provide microbiome researchers with an integrated end-to-end solution for accurate microbiome analysis. Both companies will present the integrated solution for microbiome research to the public at the ASM Microbe conference (CosmosID will be at booth 1309, and Zymo Research will be at Booth 2931) in Atlanta, from June 7-11, 2018.
 
The partnership combines Zymo Research’s complete microbiomics product portfolio from sample collection/preservation, mock microbial community standards, nucleic acid isolation and library preparation with the largest curated microbiome database, maintained and powered by CosmosID. The combined technologies of both companies will allow for comprehensive and simple service for multi-kingdom microbiome analysis, not limiting the identification to only bacterial constituents of microbial communities, but also covering other microbial kingdoms such as fungi.
 
“The partnership between CosmosID and Zymo Research is a perfect match for our customers.” said Manoj Dadlani, CEO of CosmosID. “CosmosID is powered by the largest database of microbial genome information which enables strain level resolution of bacteria, archaea, protists, fungi, viruses and even unknown microorganisms, and Zymo Research’s pipeline has proven it can consistently prepare samples that accurately reflect microbial compositions.”
  
As a part of the first stage of the partnership CosmosID and Zymo Research are tackling the challenge of bias and irreproducibility in the field of microbiomics head-on. Microbial composition profiling powered by Next-Generation sequencing has become routine — however these techniques are complex, and can suffer from significant bias from collection to analysis. By adding defined and controlled Microbial Community Standards to a workflow or even within microbiome samples, researchers can assess, improve and compare bias and errors in the metagenomics workflow.
 
Completing the first stage of this collaboration, CosmosID will release an update to its widely used cloud-based bioinformatics platform for microbiome analysis during this year’s ASM Microbe conference in Atlanta. The update introduces new, user friendly tools to analyze internal microbiome standards from Zymo Research and to automatically assess the quality of analyzed sequence data.  Data generated using the sophisticated yet streamlined pipeline for the analysis of Zymo Research microbiome standards can be conveniently interpreted – free of additional charge – via CosmosID’s user-friendly Cloud-based bioinformatics platform.
 
“The synergy of this partnership is very exciting because of the tremendous value we collectively bring to our customers by combining Zymo Research’s portfolio of products designed from collection to conclusion for accurate and reproducible microbiome measurements with CosmosID’s multi-kingdom strain-level resolution and industry leading sensitivity and precision,” noted Ryan Kemp, Director of Nucleic Acid Solutions at Zymo Research. “Combined, our metagenomics solution has become both the most powerful and simplest collection to conclusion solution available.”

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue